Phase 2 N=18 Use of F-652 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=91 Effects of SAMe in Patients With Alcoholic Liver Disease
Liver Disease, Alcoholic
Primary: Changes in Serum AST Levels — -13.5; -56 Units per liter (U/L)
Phase 4 N=130 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
Alcoholic Liver Disease
Primary: Liver Enzymes(ALT) — 66; 48 IU/L
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Phase 4 N=180 Baclofen to Reduce Alcohol Use in Veterans With HCV
Hepatitis C · Alcohol Use Disorders
Primary: Number of Drinking Days in the Past Two Weeks — 8.6; 8.9; 6.8; 7.1 Number of Drinking Days/2 weeks — p=<0.01
Phase 4 N=16 Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
Genotype 1 Hepatitis C Virus
Primary: The Number of Subjects Who Achieve Negative RNA in Alcoholics — 14 Participants
Phase 2 N=4 A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Survival at Day 29 of the Assigned Treatment — 2; 0; 1; 1 Participants
N/A N=30 Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
Alcohol Consumption
Primary: Change in Bile Salt Metabolism (C4 )Levels to Determine Effect of FXR
N/A N=138 Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C
Hepatitis C · Alcohol Abuse
Primary: Change in Days of Unhealthy Alcohol Consumption — 5.46; 7.16; 2.72; 5.56 Unhealthy drinking days in last 30
Phase 3 N=104 Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
Acute Alcoholic Hepatitis
Primary: 180 Days Mortality — 17; 22; 0 Participants — p=.30
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
N/A N=33 Alcohol Biosensor Monitoring for Alcoholic Liver Disease
Alcohol Use, Unspecified
Primary: Alcohol Use — 7.4; 5.3; 4.4 drinks per episode
Phase 2 N=147 Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Survival at 90 Days — 90; 70 percentage of participants
N/A N=1,133 Alcoholic Hepatitis Network Observational Study
Alcoholic Hepatitis
Primary: Number of Subjects With Clinical Data Collected — 717; 257; 159 Participants
N/A N=139 Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
Alcohol Dependence · Chronic Hepatitis C
Primary: The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up. — 14.88; 21.41 Standard Alcohol drinks
Phase 2 N=40 Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content — 8.38; 7.72; 8.50; 7.29 percentage of liver fat content — p=0.94
Phase 2 N=55 IL-1 Signal Inhibition in Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline. — 14; 10 Participants…
N/A N=14 Team Science (The Liver Health Study)
Steatotic Liver Disease of Mixed Origin (MetALD)
Primary: Proportion Screened With Alcohol Intake and Weight-related Risks for Metabolism and Alcohol-associated Liver Disease — 26 Participants
Phase 2 N=18 Treating Nonalcoholic Steatohepatitis With Pioglitazone
Hepatitis
Primary: Number of Patients With Improvement in Liver Histology — 12 participants
N/A N=51 Obesity and Nonalcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Hepatic Insulin Sensitivity Index (HISI) — 0.8; 1.4 [10000/(μmol/min)x(mU/L)] — p=<0.019
N/A N=46 HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
Hepatitis C · Alcohol Use Disorder
Primary: Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores — 10.99; 0.31; 6.35 Units on a scale
Phase 2 N=40 Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment — 2.46; 3.61 percentage of liver fat content
Phase 2 N=19 A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Lille Model for Alcoholic Hepatitis Score — 0.020; 0.050; 0.155; 0.195 score on a scale
Phase 2 N=57 Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis
Hepatitis, Alcoholic
Primary: Gastrointestinal Safety Endpoints — 15; 27; 7; 14 Incidents
Phase 2 N=53 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
Phase 2 N=104 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)
Alcoholic Hepatitis (AH)
Primary: Percentage of Participants With Treatment-Emergent (TE) Adverse Events (AE), Serious AEs (SAE), AEs Leading to Premature Study Drug Discontinuation, and Grade 3 or 4…
Phase 2 N=32 Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants
Phase 2 N=155 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Phase 4 N=10 The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
Chronic Hepatitis · Chronic Hepatitis C · Chronic Alcoholic Hepatitis
Primary: The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks — 77.5; 105.5 IU/L
N/A N=1,061 Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants